457 related articles for article (PubMed ID: 15504286)
21. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
22. Effects of HBV gene variations on disease development and antiviral therapy for patients with chronic hepatitis B.
Chen JY; Wang LW; Sun XM; Gong ZJ
Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):393-7. PubMed ID: 16109523
[TBL] [Abstract][Full Text] [Related]
23. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy.
Di Marco V; Di Stefano R; Ferraro D; Almasio PL; Bonura C; Giglio M; Parisi P; Cappello M; Alaimo G; Craxì A
Antivir Ther; 2005; 10(3):431-9. PubMed ID: 15918334
[TBL] [Abstract][Full Text] [Related]
24. [One year and half treatment with lamivudine in active cirrhosis resulting from chronic hepatitis B].
Zeng WQ; Guo SH; Zhang DZ; Zhou Z; Ren H; Zhang QH; Wang ZY
Zhonghua Gan Zang Bing Za Zhi; 2003 Mar; 11(3):176-8. PubMed ID: 12681069
[TBL] [Abstract][Full Text] [Related]
25. Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients.
Woo HY; Park H; Kim BI; Jeon WK; Cho YK; Kim YJ
Antivir Ther; 2007; 12(1):7-13. PubMed ID: 17503742
[TBL] [Abstract][Full Text] [Related]
26. A real-time quantitative polymerase chain reaction method for hepatitis B virus in patients with chronic hepatitis B treated with lamivudine.
Ide T; Kumashiro R; Koga Y; Tanaka E; Hino T; Hisamochi A; Murashima S; Ogata K; Tanaka K; Kuwahara R; Sata M
Am J Gastroenterol; 2003 Sep; 98(9):2048-51. PubMed ID: 14499786
[TBL] [Abstract][Full Text] [Related]
27. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
[TBL] [Abstract][Full Text] [Related]
28. [Effects comparison of lamivudine therapy for hepatitis B virus genotypes B and C].
Zhou JL; Wu SP
Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):489-90. PubMed ID: 15329211
[TBL] [Abstract][Full Text] [Related]
29. [Clinical characteristics of and the related factors to the relapse of chronic hepatitis B after lamivudine withdrawal].
Zhang XH; Lin GL; Zhu JY; Chen L; Yang SJ; Xiao JS
Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):601-4. PubMed ID: 15504290
[TBL] [Abstract][Full Text] [Related]
30. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
Shin JW; Chung YH; Choi MH; Kim JA; Ryu SH; Jang MK; Kim IS; Park NH; Lee HC; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
[TBL] [Abstract][Full Text] [Related]
31. Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B.
Feng B; Wei L; Chen M; Wang L
Microbiol Res; 2008; 163(4):487-92. PubMed ID: 17317127
[TBL] [Abstract][Full Text] [Related]
32. Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B.
Buti M; Sánchez F; Cotrina M; Jardi R; Rodríguez F; Esteban R; Guardia J
J Infect Dis; 2001 Apr; 183(8):1277-80. PubMed ID: 11262212
[TBL] [Abstract][Full Text] [Related]
33. [Clinical efficacy of lamivudine in the treatment of chronic hepatitis B].
Ma H; You H; Yin S
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Jun; 15(2):147-9. PubMed ID: 11436644
[TBL] [Abstract][Full Text] [Related]
34. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.
Tsubota A; Arase Y; Suzuki F; Kobayashi M; Matsuda M; Sato J; Suzuki Y; Akuta N; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
J Med Virol; 2004 May; 73(1):7-12. PubMed ID: 15042641
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.
Lai CL; Dienstag J; Schiff E; Leung NW; Atkins M; Hunt C; Brown N; Woessner M; Boehme R; Condreay L
Clin Infect Dis; 2003 Mar; 36(6):687-96. PubMed ID: 12627352
[TBL] [Abstract][Full Text] [Related]
36. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine.
Hatakeyama T; Noguchi C; Hiraga N; Mori N; Tsuge M; Imamura M; Takahashi S; Kawakami Y; Fujimoto Y; Ochi H; Abe H; Maekawa T; Kawakami H; Yatsuji H; Aisaka Y; Kohno H; Aimitsu S; Chayama K
Hepatology; 2007 May; 45(5):1179-86. PubMed ID: 17465002
[TBL] [Abstract][Full Text] [Related]
37. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.
Akarsu M; Sengonul A; Tankurt E; Sayiner AA; Topalak O; Akpinar H; Abacioglu YH
J Gastroenterol Hepatol; 2006 Dec; 21(12):1783-8. PubMed ID: 17074014
[TBL] [Abstract][Full Text] [Related]
38. A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis.
Nishida T; Kobashi H; Fujioka S; Fujio K; Takaguchi K; Ikeda H; Kawaguchi M; Ando M; Araki Y; Higashi T; Shoji B; Takaki A; Iwasaki Y; Sakaguchi K; Shiratori Y; Yamamoto K
J Gastroenterol Hepatol; 2008 May; 23(5):794-803. PubMed ID: 18086120
[TBL] [Abstract][Full Text] [Related]
39. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
[TBL] [Abstract][Full Text] [Related]
40. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.
Sponseller CA; Bacon BR; Di Bisceglie AM
Liver Transpl; 2000 Nov; 6(6):715-20. PubMed ID: 11084057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
